Seeking Alpha

MannKind (MNKD -11.8%) shares plummet after the company reports a Q1 loss and says its...

MannKind (MNKD -11.8%) shares plummet after the company reports a Q1 loss and says its end-of-review meeting with the FDA over its inhaled insulin Afrezza was productive. But trials will run through at least late 2012, and cash could run out by then. "It is not an overstatement to say that everything is riding on the future regulatory and commercial success of Afrezza," a Baird analyst says.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs